
Practical Lipid Management
Concepts and Controversies
Wiley (Publisher)
1st Edition
Will be published approx. on 10. October 2008
Book
Hardback
256 pages
978-0-470-05690-5 (ISBN)
Description
A practical text on the clinical management of dyslipidemias, Practical Lipid Management balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism.
The book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to interpreting the results of clinical trials. A feature of the book is a set of sidebars which explore current controversies and unanswered questions in clinical lipidology. The treatment of specific dyslipidemias is illustrated with case studies. Treatment algorithms are also provided.
Practical Lipid Management
* details the relationship between specific lipids, lipoproteins and cardiovascular disease
* provides guidance on the etiology and diagnosis of lipid abnormalities
* summarizes current understanding of atherogenesis
* reviews the evidence base for the use of therapeutic lifestyle change and specific lipid-lowering medications to reduce morbidity and mortality from cardiovascular disease
* includes a cutting edge discussion of the controversies arising from the results of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial
Practical Lipid Management provides a concise summary of best practice according to various international guidelines, making it a useful tool for all primary care physicians and others involved in the management of diseases such as diabetes, cardiovascular disease and stroke. It will serve as an evidence-based, rapid, and valuable resource for family physicians, internists, nurse practitioners, physician assistants, cardiologists, endocrinologists and allied health professionals involved in the care of patients with lipid disorders.
Reviews / Votes
"This is an essential book for physicians who manage patients with lipid disorders. There is no comparable book that provides the depth of information this one does while remaining practical in approach." (Doody's, September 2009)More details
Product info
GB
Edition
1., Auflage
Language
English
Place of publication
New York
United States
Target group
Professional and scholarly
Product notice
sewn/stitched
Paper over boards
Dimensions
Height: 198 mm
Width: 130 mm
Thickness: 20 mm
Weight
363 gr
ISBN-13
978-0-470-05690-5 (9780470056905)
Schweitzer Classification
Other editions
Additional editions

E-Book
10/2008
Wiley
€71.99
Available for download
Persons
Peter P. Toth, M.D., Ph.D., FAAFP, FICA, FAHA, FACC. Director of Preventive Cardiology, Sterling Rock Falls Clinic, Ltd., Illinois, USA; Chief of Medicine, CGH Medical Center, Illinois, USA; Visiting Clinical Associate Professor, University of Illinois School of Medicine, USA; Editor-in-Chief, Journal of Applied Research?in Clinical and Experimental Therapeutics.
Kevin C. Maki, PhD. President, Provident Clinical Research & Consulting, Inc., USA.
Kevin C. Maki, PhD. President, Provident Clinical Research & Consulting, Inc., USA.
Content
Foreword.
Preface.
Acknowledgements.
Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview.
Controversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?
Chapter 2 Vascular Biology and Atherogenesis.
Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults.
Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?
Chapter 4 Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome.
Chapter 5 Management of Elevated Low-Density Lipoprotein Cholesterol.
Controversy: How Low Should We Go?
Controversy: Risks and Benefits of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy.
Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on "How Low You Go" or also on "How You Get There"?
Chapter 6 Management of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol.
Controversy: Do we Need a Triglyceride Treatment Target to Insure a Predominance of Larger, More Buoyant LDLParticles?
Chapter 7 Management of Depressed High-Density Lipoprotein Cholesterol.
Controversy: Do we Need HDL Treatment Goals?
Chapter 8 Lipid Management in Population Subsets: Women, the Elderly, Ethnic Minorities, Children, and Adolescents.
Chapter 9 Emerging Risk Factors and Biomarkers of Cardiovascular Disease.
Chapter 10 A Primer on Clinical Trials and Critical Review of Clinical Trial Reports for the Clinician.
Chapter 11 Case Studies.
Index.